Key result
Fondaparinux reduced the incidence of VTE in acutely ill medical patients (5.6% vs 10.5% with placebo; P=0.029) and demonstrated efficacy across various surgical and medical settings.
Why the study?
Does fondaparinux improve the prevention and treatment of thrombosis compared to standard therapies or placebo in various medical and surgical settings?
Does fondaparinux improve the prevention and treatment of thrombosis compared to standard therapies or placebo in various medical and surgical settings?
Fondaparinux is an effective and safe option for the prevention and treatment of venous thromboembolism across a wide range of medical and surgical settings.
No takes yet. Share an insight, caveat, or question.
May support fondaparinux for VTE prevention in medical patients; hypothesis-generating across settings and requires contemporary randomized confirmation.
Rupert Bauersachs (2005) conducted a review in Venous thromboembolism (VTE). Fondaparinux vs. Dalteparin, placebo, enoxaparin, unfractionated heparin was evaluated on Venous thromboembolism (VTE). Fondaparinux reduced the incidence of VTE in acutely ill medical patients (5.6% vs 10.5% with placebo; P=0.029) and demonstrated efficacy across various surgical and medical settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: